Thursday, March 30, 2006

AVI BioPharma Up Bird Flu Trial Plan: Financial News - Yahoo! Finance

"Shares of AVI BioPharma Inc. jumped Thursday after the biotech company said it plans to file papers with the Food and Drug Administration this year to begin clinical trials of its Neugene line of antisense drugs.

AVI BioPharma rose 79 cents, or 12 percent, to $7.38 in afternoon trading on the Nasdaq at more than double their average volume. Shares have traded between $2.05 and $9.20 over the past 52 weeks."

No comments: